Government Aims To Make India A Global Biotech Hub By 2020

Source: IBEF.org, Mar 21, 2017

New Delhi: The Minister of State for Science and Technology & Earth Sciences, Mr. Y. S. Chowdary, has said that biotechnology will be the leader among the knowledge based industries of the 21st century. He said producing affordable products will be major issue for India. He called for efforts to set up a proper ecosystem with sustainable systems, particularly in hubs of rural India. The Minister was speaking after inaugurating the 5th Foundation Day of Biotechnology Industry Research Assistance Council (BIRAC), Department of Bio-Technology at New Delhi today.

Mr. Y. S. Chowdary, further said that – “Research and innovation has been one of the key areas emphasized by the Prime Minister. Globally, BIRAC has been hailed as one of the most effective government measures to create an enabling environment for research and development to flourish in a country. We aim to develop India into a global innovation hub by 2020 and BIRAC has paved the way to deliver on that mandate.”

Read the rest of this entry »

Advertisements

Merck plans India bio-production plant

indexNew Delhi: German healthcare and life sciences firm Merck KGaA may set up a bio-production plant in India to help local companies create biotech drugs and biosimilars (copies of off-patent bio-tech drugs). The plant will be its fourth such globally, a top executive for the company toldMint.

“We would be open to set up a bio-production centre. We have one in France and we have opened one in the US. We will open another one in China. Because we believe that demand in these three geographies is undisputed; as it is in India,” Udit Batra, member of the executive board of Merck KGaA and chief executive of its life science business, which contributes 44% of the firm’s global revenue, said in an interview on Friday.

Read the rest of this entry »

Govt expects biotech sector to hit $100 billion by 2025

index.jpgSource: Business Standard, Jan 19, 2017

New Delhi: The government is targeting the country’s biotechnology industry to reach $100 billion by 2025, as it works to develop India into a world-class biomanufacturing hub.

The sector, which is currently growing at 20 per cent, is expected to go up to $11.6 billion by 2017, according to the achievement report of the sector under government’s ‘Make in India’ initiative.

Read the rest of this entry »

Biocon hits fresh record high as EMA accepts biosimilar for review

indexMumbai: Shares of Biocon hit a fresh record high of Rs 910, up 5% on the BSE in early morning trade, after the company announced Mylan’s application to market biosimilar Trastuzumab has been accepted by the European Medicines Agency (EMA) for review. The biosimilar Trastuzumab is used to treat certain breast and gastric cancers.

“Mylan and Biocon, which have co-developed this popular biosimilar, anticipate that this may be the first Marketing Authorization Application (MAA) for a biosimilar Trastuzumab accepted by the EMA for review,” Mylan and Biocon said in a joint press release.

“This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe,” it added.The filing includes analytical, functional and pre-clinical data and results from the pharmacokinetics and confirmatory safety global clinical trials for Trastuzumab, the company said.

At 09:29 am, the stock was up 4.7% at Rs 906 on the BSE, as compared to 0.29% rise in the S&P BSE Sensex. The counter has seen huge trading volumes with a combined 1.26 million equity shares changing hands in first 15 minutes of trade on the NSE and BSE.

Biocon links with Mexico’s PiSA to tap US insulin market

indexSource: The Economic Times, Mar 17, 2016

MUMBAI: India’s largest biotechnology company Biocon said it has entered into a co-development and commercialization alliance with PiSA of Mexico for recombinant human insulin aimed at the US market.

The partnership with the Mexican insulins major will help Biocon gain proximity to the US market while leveraging the country’s NAFTA membership to ensure an efficient and optimal supply chain for the US.

Read the rest of this entry »

Biocon gets approval for generic Crestor in Europe

index.jpgSource: LiveMint.com, Feb 15, 2016

Hyderabad:Biopharmaceuticals firm Biocon Ltd on Monday said it has got approval to sell the generic equivalent of Astrazenaca Plc’s cholesterol-lowering pill Crestor in the European Union (EU).

The approval is for the 5 milligram (mg), 10 mg, 20 mg and 40 mg dosage forms of the drug .Crestor, generically called rosuvastatin calcium, is Biocon’s first-ever generic formulation approval in a regulated market.

 “(It) marks an important milestone in Biocon’s small molecules strategy of forward integration from APIs to finished dosages,” Biocon said in a statement.“The approval for rosuvastatin calcium, through decentralized procedure, will open the doors for Biocon to over 15 European countries and will enable the company to address $1.2 billion opportunity, starting FY17,” the company said.

Read the rest of this entry »

India risks missing boat as biosimilars shake up drug industry

 BioTechSource: Financial Express, Oct 15, 2015

Mumbai: India, which has dominated the generic drugs industry for decades, is falling behind in the race to make copies of complex biotech drugs, which are expected to generate tens of billions of dollars in sales in the coming years.

While Indian firms have launched a few such products on the domestic market, where regulatory barriers are relatively low, they are being overtaken by European, American and South Korean firms in the race to supply lucrative Western markets.

Read the rest of this entry »